Nature Search

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Cibisatamab is a T-cell bispecific antibody targeting the carcinoembryonic antigen (CEA) on tumor cells and CD3 epsilon chain on T cells. Here the authors report the results of two clinical trials of cibisatamab as monotherapy (NCT02324257) and in combination with atezolizumab (anti-PD-L1; NCT02650713) in patients with CEA-positive solid tumors.

Neil H. Segal
Ignacio Melero
Guillem Argilés
ResearchOpen Access15 May 2024
Nature Communications

Volume: 15, P: 1-14
Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

Ignacio Melero
Maria de Miguel Luken
Eugen Leo
Amendments and CorrectionsOpen Access25 Feb 2025
Nature

Volume: 639, P: E18
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

A study reporting the results of a clinical trial co-administering the GDF-15-blocking antibody visugromab with the anti-PD-1 antibody nivolumab demonstrates that neutralizing GDF-15 can overcome resistance to immune checkpoint inhibition in cancer.

Ignacio Melero
Maria de Miguel Luken
Eugen Leo
ResearchOpen Access11 Dec 2024
Nature

Volume: 637, P: 1218-1227
In silico evaluation of the immunogenic profile of lung cancers with SMARCA4 genetic alterations

Cristina Nieto-Jiménez
Esther Garcia-Lorenzo
Alberto Ocana
ResearchOpen Access22 May 2025
Scientific Reports

Volume: 15, P: 1-11
GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

An analysis of 24,202 critical cases of COVID-19 identifies potentially druggable targets in inflammatory signalling (JAK1), monocyte–macrophage activation and endothelial permeability (PDE4A), immunometabolism (SLC2A5 and AK5), and host factors required for viral entry and replication (TMPRSS2 and RAB2A).

Erola Pairo-Castineira
Konrad Rawlik
J. Kenneth Baillie
ResearchOpen Access17 May 2023
Nature

Volume: 617, P: 764-768
MYC targeting by OMO-103 in solid tumors: a phase 1 trial

In this first-in-human phase 1 dose-escalation trial of OMO-103, a MYC inhibitor, in patients with solid tumors, treatment was safe and showed preliminary clinical activity along with demonstrated target engagement and identification of potential pharmacodynamic markers.

Elena Garralda
Marie-Eve Beaulieu
Emiliano Calvo
ResearchOpen Access06 Feb 2024
Nature Medicine

Volume: 30, P: 762-771
Genotyping, sequencing and analysis of 140,000 adults from Mexico City

Genotype and exome sequencing of 150,000 participants and whole-genome sequencing of 9,950 selected individuals recruited into the Mexico City Prospective Study constitute a valuable, publicly available resource of non-European sequencing data.

Andrey Ziyatdinov
Jason Torres
Roberto Tapia-Conyer
ResearchOpen Access11 Oct 2023
Nature

Volume: 622, P: 784-793
HER kinase inhibition in patients with HER2- and HER3-mutant cancers

In a basket trial design, the efficacy of the pan-HER kinase inhibitor neratinib is tested in patients with 21 different tumour types, and responses are determined by mutation and tissue type, and are restricted to HER2-mutant cancers.

David M. Hyman
Sarina A. Piha-Paul
David B. Solit
Research31 Jan 2018
Nature

Volume: 554, P: 189-194
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers

David M. Hyman
Sarina A. Piha-Paul
David B. Solit
Amendments and Corrections12 Feb 2019
Nature

Volume: 566, P: E11-E12
Author Correction: Genotyping, sequencing and analysis of 140,000 adults from Mexico City

Andrey Ziyatdinov
Jason Torres
Roberto Tapia-Conyer
Amendments and CorrectionsOpen Access08 Feb 2024
Nature

Volume: 626, P: E18
Author Correction: GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Erola Pairo-Castineira
Konrad Rawlik
J. Kenneth Baillie
Amendments and CorrectionsOpen Access11 Jul 2023
Nature

Volume: 619, P: E61
Shaping current European mitochondrial haplogroup frequency in response to infection: the case of SARS-CoV-2 severity

Genetic and Structural analysis of COVID patients cohort reveals a correlation between mitochondrial haplogroup and SARS-CoV-2 severity.

José Luis Cabrera-Alarcon
Raquel Cruz
José Antonio Enriquez
ResearchOpen Access09 Jan 2025
Communications Biology

Volume: 8, P: 1-12
A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours

Jayesh Desai
Peter Fong
Juan Martin-Liberal
ResearchOpen Access16 Feb 2023
British Journal of Cancer

Volume: 128, P: 1418-1428
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors

Anthony B. El-Khoueiry
James Clarke
Albiruni R. Abdul Razak
ResearchOpen Access26 May 2023
British Journal of Cancer

Volume: 129, P: 309-317
Combined use of a healthy lifestyle smartphone application and usual primary care counseling to improve arterial stiffness, blood pressure and wave reflections: a Randomized Controlled Trial (EVIDENT II Study)

José I. Recio-Rodríguez
Emiliano Rodriguez-Sanchez
Luis Garcia-Ortiz
Research26 Dec 2018
Hypertension Research

Volume: 42, P: 852-862
A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours

Debbie G. J. Robbrecht
Juanita Lopez
Johann S. de Bono
ResearchOpen Access06 Oct 2020
British Journal of Cancer

Volume: 124, P: 391-398
Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality.

Luis A. Pérez-Jurado
Alejandro Cáceres
Juan R. González
ResearchOpen Access19 Feb 2024
Communications Biology

Volume: 7, P: 1-14

Search

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

In silico evaluation of the immunogenic profile of lung cancers with SMARCA4 genetic alterations

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

MYC targeting by OMO-103 in solid tumors: a phase 1 trial

Genotyping, sequencing and analysis of 140,000 adults from Mexico City

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Author Correction: Genotyping, sequencing and analysis of 140,000 adults from Mexico City

Author Correction: GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Shaping current European mitochondrial haplogroup frequency in response to infection: the case of SARS-CoV-2 severity

A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours

Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors

Combined use of a healthy lifestyle smartphone application and usual primary care counseling to improve arterial stiffness, blood pressure and wave reflections: a Randomized Controlled Trial (EVIDENT II Study)

A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

Search

Quick links

Search

Filter By:

Search

Quick links